MAX Chat
Share chart Longboard Pharmaceuticals, Inc.
Extended chart
Simple chart
About Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. Its lead product candidate is LP352, which is in Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. The company's preclinical product candidate includes LP659 which focuses on developing therapies for multiple neurological diseases; and LP143. It also entered into license agreement with Arena Pharmaceuticals Inc. to develop and commercialize LP352, LP659, LP143, and other compounds. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Main settings
IPO date
2021-03-12
ISIN
US54300N1037
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 0 | 0 |
| P/BV | 3.44 | 5 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -107.35 | 0 |
| ROE | -132.99 | 0 |
| ROIC | 0 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.0084 | 10 |
| Debt/Ratio | 0.0094 | 10 |
| Debt/Equity | 0.2388 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 0 | 0 |
| Yield Ebitda, % | 294.13 | 10 |
| Yield EPS, % | 181.33 | 10 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 59.98 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 59.98 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Month | 59.98 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Three month | 59.98 $ | 59.98 $ | 59.98 $ | 0 % | 0 % | 0 % |
| Half a year | 59.98 $ | 59.98 $ | 59.98 $ | 0 % | 0 % | 0 % |
| Year | 35.2 $ | 27.58 $ | 59.98 $ | +70.4 % | 0 % | 0 % |
| 3 years | 3.65 $ | 2.95 $ | 59.98 $ | +1 543.29 % | 0 % | 0 % |
| 5 years | 2.95 $ | 2.95 $ | 59.98 $ | +2 033.22 % | 0 % | 0 % |
| 10 years | 2.95 $ | 2.95 $ | 59.98 $ | +2 033.22 % | 0 % | 0 % |
| Year to date | 59.98 $ | 59.98 $ | 59.98 $ | 0 % | 0 % | 0 % |
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
| iShares Morningstar Small-Cap Value ETF | 0.02069 | 175.74 | 0.06 |
| iShares Morningstar Small-Cap ETF | 0.01851 | 301.34 | 0.25 |
| iShares Morningstar Small-Cap Growth ETF | 0.01676 | 570.49 | 0.06 |
| 0.02 | 349.19 | 0.12 |
|---|
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Kevin R. Lind | President, CEO, Secretary & Director | 1.07M | 1976 (49 years) |
| Ms. Brandi L. Roberts CPA, M.B.A. | Executive VP & CFO | 662.65k | 1974 (51 year) |
| Dr. Randall E. Kaye M.D. | Executive VP & Chief Medical Officer | 717.95k | 1962 (63 years) |
| Mr. Chadwick J. Orevillo MPH | Executive VP & Head of Operations | N/A | |
| Mr. Steven W. Spector J.D. | Executive VP, Head of Business Development & General Counsel | N/A | 1965 (60 years) |
| Dr. Anne M. Danks Ph.D. | VP & Head of Nonclinical Research & Development | N/A | |
| Mr. Gus Cardenas | VP & Head of Quality Assurance | N/A | |
| Dr. Marco Peters Ph.D. | VP & Head of Translational Science | N/A | |
| Dr. Dewey McLin Ph.D. | VP & Head of Medical Affairs | N/A | |
| Ms. Megan E. Knight | VP & Head of Investor Relations |
About company
Address: United States, La Jolla. CA, 4275 Executive Square - Open in google maps, Open in yandex maps
Website: https://www.longboardpharma.com
Website: https://www.longboardpharma.com
